{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:12:26Z","timestamp":1778141546951,"version":"3.51.4"},"reference-count":6,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["Indian J Dermatol Venereol Leprol"],"DOI":"10.25259\/ijdvl_226_2024","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T06:16:58Z","timestamp":1717049818000},"page":"394-395","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The perils of prescribing second line anti-leprosy therapy for erythema nodosum leprosum ignoring resistance testing data"],"prefix":"10.25259","volume":"92","author":[{"given":"Aishwarya","family":"Muddebihal","sequence":"first","affiliation":[{"name":"Department of Dermatology, Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Manohar Lohia Hospital, Delhi, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kabir","family":"Sardana","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Manohar Lohia Hospital, Delhi, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharmesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Manohar Lohia Hospital, Delhi, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Manohar Lohia Hospital, Delhi, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"10.25259\/IJDVL_226_2024\/ref-1","first-page":"202","article-title":"Immunopathogenesis of reactions","volume-title":"Jopling\u2019s Handbook of Leprosy","author":"Khurana","year":"2023","edition":"7th ed"},{"key":"10.25259\/IJDVL_226_2024\/ref-3","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1111\/jdv.18709","article-title":"A prospective case control study of resistance to rifampicin, dapsone and ofloxacin in Type 1 and Type 2 leprosy reactions and the therapeutic impact of modified treatment regimen on reactions","volume":"37","author":"Muddebihal","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_226_2024\/ref-4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jgar.2023.10.006","article-title":"High frequency of ofloxacin resistance patterns of Mycobacterium leprae from India: An indication to revisit second line anti-leprosy treatment regimen","volume":"35","author":"Chhabra","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"10.25259\/IJDVL_226_2024\/ref-5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/imr.12960","article-title":"Susceptibility and resistance in leprosy: Studies in the mouse model","volume":"301","author":"Adams","year":"2021","journal-title":"Immunol Rev"},{"key":"10.25259\/IJDVL_226_2024\/ref-6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/ijd.16315","article-title":"A real-world study of low-dose thalidomide in severe erythema nodosum leprosum highlighting its mechanistic rationale in a resource-constrained target population","volume":"62","author":"Bathula","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_226_2024\/ref-7","doi-asserted-by":"publisher","first-page":"e0003431","DOI":"10.1371\/journal.pntd.0003431","article-title":"Household costs of leprosy reactions (ENL) in rural India","volume":"9","author":"Chandler","year":"2015","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/the-perils-of-prescribing-second-line-anti-leprosy-therapy-for-erythema-nodosum-leprosum-ignoring-resistance-testing-data\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/the-perils-of-prescribing-second-line-anti-leprosy-therapy-for-erythema-nodosum-leprosum-ignoring-resistance-testing-data\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:32:23Z","timestamp":1778139143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/the-perils-of-prescribing-second-line-anti-leprosy-therapy-for-erythema-nodosum-leprosum-ignoring-resistance-testing-data\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":6,"alternative-id":["10.25259\/IJDVL_226_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_226_2024","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"article-number":"394"}}